26.9.2024 08:00:00 CEST | Thor Medical ASA | Non-regulatory press releases
Oslo, 26 September 2024: Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, has today reached mechanical completion of the Herøya pilot production facilities and initiated commissioning.
“The construction of the pilot facilities has been completed on time and budget, and with raw materials already in place at Herøya we are on track to begin production in October and deliver the first product samples to customers before the end of the year. This marks an important milestone as we move forward towards commercial operations.”, says Jasper Kurth, CEO of Thor Medical.
The pilot facilities will be used to verify production processes and product quality and produce product samples for customer validation, and will also serve as a platform for a scale-up to commercial production.
Thor Medical already has a concept study ongoing for the next phase of commercial-scale production, with an investment decision expected by the end of the first quarter 2025.
Disclosure regulation
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
Contacts
Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no
About Thor Medical ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
To learn more, visit www.thormedical.no.
Attachments
Download announcement as PDF.pdf
